| Cover - shares | 9 Months Ended | |
| Sep. 30, 2024 | Nov. 19, 2024 | |
| Cover [Abstract] | ||
| Document Type | 10-Q | |
| Amendment Flag | false | |
| Document Quarterly Report | true | |
| Document Transition Report | false | |
| Document Period End Date | Sep. 30, 2024 | |
| Document Fiscal Period Focus | Q3 | |
| Document Fiscal Year Focus | 2024 | |
| Current Fiscal Year End Date | --12-31 | |
| Entity File Number | 000-30991 | |
| Entity Registrant Name | SKINOVATION PHARMACEUTICAL INCORPORATED | |
| Entity Central Index Key | 0001118072 | |
| Entity Tax Identification Number | 87-0458170 | |
| Entity Incorporation, State or Country Code | WY | |
| Entity Address, Address Line One | 440 East 400 South | |
| Entity Address, Address Line Two | Ste 300 | |
| Entity Address, City or Town | Salt Lake City | |
| Entity Address, State or Province | UT | |
| Entity Address, Postal Zip Code | 84111 | |
| City Area Code | (801) | |
| Local Phone Number | 323-2395 | |
| Entity Current Reporting Status | Yes | |
| Entity Interactive Data Current | Yes | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Small Business | true | |
| Entity Emerging Growth Company | true | |
| Elected Not To Use the Extended Transition Period | false | |
| Entity Shell Company | true | |
| Entity Common Stock, Shares Outstanding | 708,000 |
| Condensed Balance Sheets (Unaudited) - USD ($) | Sep. 30, 2024 | Dec. 31, 2023 |
| Current Assets | ||
| Cash | $ 1,844 | $ 16,234 |
| Total Current Assets | 1,844 | 16,234 |
| Total Assets | 1,844 | 16,234 |
| Current Liabilities | ||
| Accounts payable | 10,500 | 6,000 |
| Notes payable | 286,021 | 286,021 |
| Accrued interest | 188,574 | 171,414 |
| Total Current Liabilities | 485,095 | 463,435 |
| Total Liabilities | 485,095 | 463,435 |
| Commitments and Contingencies | ||
| Stockholders’ Deficit | ||
| Preferred stock, $.001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding | ||
| Common stock, $.001 par value; 50,000,000 shares authorized; 708,000 shares issued and outstanding | 708 | 708 |
| Additional paid-in capital | 25,148 | 25,148 |
| Accumulated deficit | (509,107) | (473,057) |
| Total Stockholders' Deficit | (483,251) | (447,201) |
| Total Liabilities and Stockholders' Deficit | $ 1,844 | $ 16,234 |
| Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares | Sep. 30, 2024 | Dec. 31, 2023 |
| Statement of Financial Position [Abstract] | ||
| Preferred Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 |
| Preferred Stock, Shares Authorized | 25,000,000 | 25,000,000 |
| Preferred Stock, Shares Issued | 0 | 0 |
| Preferred Stock, Shares Outstanding | 0 | 0 |
| Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 |
| Common Stock, Shares Authorized | 50,000,000 | 50,000,000 |
| Common Stock, Shares, Issued | 708,000 | 708,000 |
| Common Stock, Shares, Outstanding | 708,000 | 708,000 |
| Condensed Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
| Sep. 30, 2024 | Sep. 30, 2023 | Sep. 30, 2024 | Sep. 30, 2023 | |
| Income Statement [Abstract] | ||||
| REVENUES | ||||
| OPERATING EXPENSES | ||||
| General and administrative | 4,890 | 2,899 | 18,890 | 11,529 |
| TOTAL EXPENSES | 4,890 | 2,899 | 18,890 | 11,529 |
| Loss from operations | (4,890) | (2,899) | (18,890) | (11,529) |
| OTHER INCOME (EXPENSE) | ||||
| Interest expense | (5,720) | (5,038) | (17,160) | (15,378) |
| Total other income (expense) | (5,720) | (5,038) | (17,160) | (15,378) |
| LOSS BEFORE INCOME TAXES | (10,610) | (7,937) | (36,050) | (26,907) |
| INCOME TAX EXPENSE | ||||
| NET LOSS | $ (10,610) | $ (7,937) | $ (36,050) | $ (26,907) |
| Basic and diluted net loss per share | $ (0.01) | $ (0.01) | $ (0.05) | $ (0.04) |
| Basic and diluted weighted average shares outstanding | 708,000 | 708,000 | 708,000 | 708,000 |
| Condensed Statements of Stockholders' Deficit (Unaudited) - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
| Balance – December 31, 2023 at Dec. 31, 2022 | $ 708 | $ 25,148 | $ (437,191) | $ (411,335) |
| Shares, Outstanding, Beginning Balance at Dec. 31, 2022 | 708,000 | |||
| Net loss | (10,780) | (10,780) | ||
| Balance – September 30, 2024 at Mar. 31, 2023 | $ 708 | 25,148 | (447,971) | (422,115) |
| Shares, Outstanding, Ending Balance at Mar. 31, 2023 | 708,000 | |||
| Balance – December 31, 2023 at Dec. 31, 2022 | $ 708 | 25,148 | (437,191) | (411,335) |
| Shares, Outstanding, Beginning Balance at Dec. 31, 2022 | 708,000 | |||
| Net loss | (26,907) | |||
| Balance – September 30, 2024 at Sep. 30, 2023 | $ 708 | 25,148 | (464,098) | (438,242) |
| Shares, Outstanding, Ending Balance at Sep. 30, 2023 | 708,000 | |||
| Balance – December 31, 2023 at Mar. 31, 2023 | $ 708 | 25,148 | (447,971) | (422,115) |
| Shares, Outstanding, Beginning Balance at Mar. 31, 2023 | 708,000 | |||
| Net loss | (8,190) | (8,190) | ||
| Balance – September 30, 2024 at Jun. 30, 2023 | $ 708 | 25,148 | (456,161) | (430,305) |
| Shares, Outstanding, Ending Balance at Jun. 30, 2023 | 708,000 | |||
| Net loss | (7,937) | (7,937) | ||
| Balance – September 30, 2024 at Sep. 30, 2023 | $ 708 | 25,148 | (464,098) | (438,242) |
| Shares, Outstanding, Ending Balance at Sep. 30, 2023 | 708,000 | |||
| Balance – December 31, 2023 at Dec. 31, 2023 | $ 708 | 25,148 | (473,057) | (447,201) |
| Shares, Outstanding, Beginning Balance at Dec. 31, 2023 | 708,000 | |||
| Net loss | (15,771) | (15,771) | ||
| Balance – September 30, 2024 at Mar. 31, 2024 | $ 708 | 25,148 | (488,828) | (462,972) |
| Shares, Outstanding, Ending Balance at Mar. 31, 2024 | 708,000 | |||
| Balance – December 31, 2023 at Dec. 31, 2023 | $ 708 | 25,148 | (473,057) | (447,201) |
| Shares, Outstanding, Beginning Balance at Dec. 31, 2023 | 708,000 | |||
| Net loss | (36,050) | |||
| Balance – September 30, 2024 at Sep. 30, 2024 | $ 708 | 25,148 | (509,107) | (483,251) |
| Shares, Outstanding, Ending Balance at Sep. 30, 2024 | 708,000 | |||
| Balance – December 31, 2023 at Mar. 31, 2024 | $ 708 | 25,148 | (488,828) | (462,972) |
| Shares, Outstanding, Beginning Balance at Mar. 31, 2024 | 708,000 | |||
| Net loss | (9,669) | (9,669) | ||
| Balance – September 30, 2024 at Jun. 30, 2024 | $ 708 | 25,148 | (498,497) | (472,641) |
| Shares, Outstanding, Ending Balance at Jun. 30, 2024 | 708,000 | |||
| Net loss | (10,610) | (10,610) | ||
| Balance – September 30, 2024 at Sep. 30, 2024 | $ 708 | $ 25,148 | $ (509,107) | $ (483,251) |
| Shares, Outstanding, Ending Balance at Sep. 30, 2024 | 708,000 |
| Condensed Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||||
| Sep. 30, 2024 | Mar. 31, 2024 | Sep. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2024 | Sep. 30, 2023 | |
| Cash Flows from Operating Activities | ||||||
| Net loss | $ (10,610) | $ (15,771) | $ (7,937) | $ (10,780) | $ (36,050) | $ (26,907) |
| Changes in operating assets and liabilities: | ||||||
| Increase in accounts payable | 4,500 | 4,500 | ||||
| Net cash used by operating activities | (14,390) | (7,029) | ||||
| Cash Flows from Investing Activities | ||||||
| Net cash used by investing activities | ||||||
| Cash Flows from Financing Activities | ||||||
| Proceeds from notes payable | 16,500 | |||||
| Net cash provided by financing activities | 16,500 | |||||
| Net increase (decrease) in cash | (14,390) | 9,471 | ||||
| Cash at beginning of period | $ 16,234 | $ 163 | 16,234 | 163 | ||
| Cash at end of period | $ 1,844 | $ 9,634 | 1,844 | 9,634 | ||
| Supplemental Cash Flow Information: | ||||||
| Cash paid for interest | ||||||
| Cash paid for income taxes | ||||||
| NOTE 1 – CONDENSED FINANCIAL STATEMENTS | 9 Months Ended |
| Sep. 30, 2024 | |
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
| NOTE 1 – CONDENSED FINANCIAL STATEMENTS | NOTE 1 – CONDENSED FINANCIAL STATEMENTS The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows as of and for the period ended September 30, 2024, and for all periods presented have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2023, audited financial statements as reported in its Form 10-K. The results of operations for the period ended September 30, 2024, are not necessarily indicative of the operating results for the full year ended December 31, 2024. |
| NOTE 2 – GOING CONCERN | 9 Months Ended |
| Sep. 30, 2024 | |
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
| NOTE 2 – GOING CONCERN | NOTE 2 – GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management’s plan to acquire or merge with other operating companies. |
| NOTE 3 – ACCOUNTS AND NOTES PAYABLE | 9 Months Ended |
| Sep. 30, 2024 | |
| Debt Disclosure [Abstract] | |
| NOTE 3 – ACCOUNTS AND NOTES PAYABLE | NOTE 3 – ACCOUNTS AND NOTES PAYABLE At September 30, 2024, and December 31, 2023, the Company had accounts payable of $ 10,500 6,000 286,021 286,021 8 Accrued interest on the notes was $ 188,574 171,414 |
| NOTE 4 – SUBSEQUENT EVENTS | 9 Months Ended |
| Sep. 30, 2024 | |
| Subsequent Events [Abstract] | |
| NOTE 4 – SUBSEQUENT EVENTS | NOTE 4 – SUBSEQUENT EVENTS The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements. |
| NOTE 3 – ACCOUNTS AND NOTES PAYABLE (Details Narrative) - USD ($) | 9 Months Ended | |
| Sep. 30, 2024 | Dec. 31, 2023 | |
| Debt Disclosure [Abstract] | ||
| Accounts Payable, Current | $ 10,500 | $ 6,000 |
| Notes Payable, Current | $ 286,021 | 286,021 |
| Debt Instrument, Interest Rate During Period | 8% | |
| Interest Payable, Current | $ 188,574 | $ 171,414 |
